UPDATE: Barclays Downgrades PharMerica (PMC) to Underweight
Tweet
Share
E-mailGet Alerts PMC Hot Sheet
Price: $29.25 --0%
Rating Summary:
3 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Rating Summary:
3 Buy, 7 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 11 | New: 14
Join SI Premium – FREE
(Updated - July 9, 2013 9:27 AM EDT)
Barclays downgraded PharMerica (NYSE: PMC) from Equalweight to Underweight with a price target of $12 (from $16). Analyst Brendan Strong thinks the market isn't accounting for potential downside after loss of two large customers, Kindred and Golden Living. With this in mind, Barclays sees downside and cut 2014 EPS to $1.10 vs the consensus of $1.51.
For an analyst ratings summary and ratings history on PharMerica click here. For more ratings news on PharMerica click here.
Shares of PharMerica closed at $13.91 yesterday.
Barclays downgraded PharMerica (NYSE: PMC) from Equalweight to Underweight with a price target of $12 (from $16). Analyst Brendan Strong thinks the market isn't accounting for potential downside after loss of two large customers, Kindred and Golden Living. With this in mind, Barclays sees downside and cut 2014 EPS to $1.10 vs the consensus of $1.51.
For an analyst ratings summary and ratings history on PharMerica click here. For more ratings news on PharMerica click here.
Shares of PharMerica closed at $13.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
- Goldman Sachs Downgrades Zhejiang Huayou Cobalt Co Ltd. (603799:CH) to Sell
- Mr. Cooper Group Inc. (COOP) PT Raised to $87 at Jefferies
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades, Hot DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
